Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01426308 · ClinicalTrials.gov registry record

Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormality Test

A clinical trial of Post-natal Cytogenetics, sponsored by Illumina.

Completed
Registry status
900
Enrollment target
3
Study locations

NCT01426308 is a study of Post-natal Cytogenetics that has completed, run by Illumina. The registered enrollment target is 900 participants. The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01426308, a study of Post-natal Cytogenetics, has completed, sponsored by Illumina.

COMPLETED
Registry status
900 participants
Enrollment target
3
Study locations

Study Summary

The study will determine the performance of the Infinium HD Test. * The primary objective of the study is to assess the performance of the Infinium HD Test using banked DNA samples extracted from whole blood patient samples derived from the intended use population. * The secondary objective of the study is to determine the background number of chromosomal abnormalities per person in the general population based on the resolution of the Infinium HD Test.

Conditions Studied

Study Locations (3)

South Carolina

  • Medical University of South Carolina - Charleston

Texas

  • Baylor College of Medicine - Houston

Utah

  • ARUP Laboratories - Salt Lake City

Trial Details

FieldValue
Enrollment Target 900 participants
Start Date 2011-08
Est. Completion 2011-11

Sponsor

Illumina

11 total trials

What the Registry Record Tells You About NCT01426308

The ClinicalTrials.gov registry entry for NCT01426308 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Illumina, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Post-natal Cytogenetics appearing as the primary indexed condition, and to 0 interventions.

NCT01426308 reports 3 study locations spanning 3 distinct geographic areas - top geographies include South Carolina, Texas, Utah.

Frequently Asked Questions

What is clinical trial NCT01426308 about?

NCT01426308 is a clinical study titled "Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormality Test". The study will determine the performance of the Infinium HD Test. * The primary objective of the study is to assess the performance of the Infinium HD Test using banked DNA samples extracted from whole blood patient samples derived from the intended use population. * The secondary objective of the ...

What is the current status of trial NCT01426308?

This trial is currently completed. The enrollment target is 900 participants. The study started on 2011-08. Estimated completion is 2011-11.

What conditions does trial NCT01426308 study?

This clinical trial studies the following conditions: Post-natal Cytogenetics.

Who is sponsoring clinical trial NCT01426308?

This trial is sponsored by Illumina, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01426308 being conducted?

This trial has 3 study locations across South Carolina, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.